Awakn Life Sciences Corp.
AWKNF · OTC
1/31/2024 | 1/31/2023 | 1/31/2022 | 1/31/2021 | |
|---|---|---|---|---|
| Revenue | $87 | $1,495 | $236 | $0 |
| % Growth | -94.2% | 533.5% | – | – |
| Cost of Goods Sold | $0 | $604 | $513 | $0 |
| Gross Profit | $87 | $892 | -$277 | $0 |
| % Margin | 100% | 59.6% | -117.3% | – |
| R&D Expenses | $828 | $1,572 | $3,309 | $0 |
| G&A Expenses | $2,728 | $4,060 | $4,396 | $667 |
| SG&A Expenses | $3,168 | $8,511 | $6,027 | $823 |
| Sales & Mktg Exp. | $440 | $1,401 | $1,630 | $103 |
| Other Operating Expenses | $18 | -$2 | $10 | $0 |
| Operating Expenses | $4,014 | $10,084 | $9,849 | $1,462 |
| Operating Income | -$3,926 | -$9,192 | -$9,794 | -$840 |
| % Margin | -4,493.9% | -614.7% | -4,149.3% | – |
| Other Income/Exp. Net | $255 | $306 | -$6,859 | -$652 |
| Pre-Tax Income | -$3,671 | -$9,652 | -$16,472 | -$1,475 |
| Tax Expense | $0 | -$509 | $0 | $0 |
| Net Income | -$5,103 | -$9,143 | -$15,946 | -$1,260 |
| % Margin | -5,840.1% | -611.4% | -6,755.7% | – |
| EPS | -0.13 | -0.36 | -0.73 | -0.1 |
| % Growth | 63.9% | 50.7% | -631.5% | – |
| EPS Diluted | -0.18 | -0.36 | -0.73 | -0.1 |
| Weighted Avg Shares Out | 29,068 | 25,203 | 21,962 | 12,629 |
| Weighted Avg Shares Out Dil | 29,068 | 25,203 | 21,962 | 12,629 |
| Supplemental Information | – | – | – | – |
| Interest Income | $88 | $306 | $0 | $13 |
| Interest Expense | $0 | $0 | $205 | $0 |
| Depreciation & Amortization | $18 | $14 | $181 | $0 |
| EBITDA | -$3,908 | -$5,263 | -$16,085 | -$840 |
| % Margin | -4,473% | -352% | -6,814.6% | – |